Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 04:01 pm EDT
Share
Sangamo Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 9.4 million compared to USD 26.46 million a year ago. Net loss was USD 104.16 million compared to USD 53.16 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.34 a year ago.
For the nine months, sales was USD 174.19 million compared to USD 84.07 million a year ago. Net loss was USD 197.54 million compared to USD 140.31 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 0.93 a year ago.
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.